Carregant...
What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
The introduction of biosimilars of biological agents for which the patents and exclusivity periods have expired is an attractive way of reducing healthcare spending through price competition with the reference product. In oncology, biosimilars of growth factors for supportive therapy were the pionee...
Guardat en:
| Publicat a: | Breast Care (Basel) |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger GmbH
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6465746/ https://ncbi.nlm.nih.gov/pubmed/31019437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496834 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|